head_bn_img

COVID-19 NAb (Colloidal Gold)

COVID-19 Neutralization Antibody

  • Screening test before vaccination
  • Monitoring results after vaccination
  • Risk assessment for infected people’s second infection
  • Risk assessment for normal people’s(including asymptomatic infection) possibility of infection
  • Virus resistance ability testing

Product Detail

Product Tags

Is your vaccine effective ?

SARS-CoV-2 (COVID19) is raging around the world, and vaccination is recognized as the most economical and effective way to control the virus epidemic. Traditional vaccine evaluation mostly uses neutralizing antibody detection methods to evaluate the effectiveness of vaccines through neutralization experiments;

Traditional methods are time-consuming and low in effificiency, usually taking 2 to 4 days to complete the evaluation, and because most of them use live viruses, It needs to be carried out in a biosafety level 3 or above laboratory, which is time-consuming and laborious, and brings great inconvenience to the evaluation of the expansion and aggregation. Therefore, there is an urgent need for a simple and rapid alternative method that is suitable for the evaluation of protective antibodies in large-scale populations.

Aehealth COVID19 Neutralization Antibody Rapid Test Kits is used of detection of COVID19 neutralination antibodies in human serum, plasma or whole blood. It can be used for rapid, highly sensitive detection in vitro. clinically used in the auxiliary evaluation of the effect of the COVID19 vaccine and evaluation of neutralization antibodies in recovered patients after infection.

Highlight Features

Easy operation

  • No need professionals to be trained
  • Compatible with multiple specimen type: Serum/Plasma/Whole blood/fingertip whole blood.

Convenient

  • No instrument required

Effificient

  • Test: 15-20 mins;

 

Highlight Features

COVID19 Neutralization Antibodies (nAbs)

Neutralization antibodies is effificiently stop the infection by blocking the interaction between the COVID19 virus and the host cells. Most neutralization antibodies respond to the receptor binding domain (RBD) of the spike protein, which binds directly to the cell surface receptor ACE2. antibodies-online currently offers two neutralization antibodies based on the clone CR3022. While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site.

It does thus not hinder binding of neutralization antibodies. While CR3022 on its own exhibits only a weak neutralization effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize COVID19.

COVID19 Neutralization Antibodies (nAbs)

  • Previous:
  • Next: